• Corpus ID: 40581213

Predicting therapeutic and aggravating drugs for hepatocellular carcinoma based on tissue-specific pathways

  title={Predicting therapeutic and aggravating drugs for hepatocellular carcinoma based on tissue-specific pathways},
  author={Liang Yu and Fengdan Xu and Lin Gao},
  journal={arXiv: Tissues and Organs},
Motivation: Hepatocellular carcinoma (HCC) is a significant health problem worldwide and annual number of cases are nearly more than 700,000. However,there are few safe and effective thera-peutic options for HCC patients.Here, we propose a new approach for predicting therapeutic and aggravating drugs for HCCbased ontissue-specificpathways, which considersnot onlyliver tis-sueand functional informationof pathways, but also the changes of single gene in pathways. Results: Firstly, we map genes… 

Figures and Tables from this paper

Innovative Drug and Disease Prediction with Dimensionality Reduction and Intelligence Based Random Walk Methods
  • S. J. Ibrahim
  • Medicine, Biology
    International Journal of Advanced Trends in Computer Science and Engineering
  • 2019
A variety of computational methods for predicting sedate disease associations have been suggested in the latest years, but there have been few algorithms dedicated to medicines for a distinct illness.


Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics.
External validation of cirrhosis and hepatocellular carcinoma serum specimens showed that this combination biomarker, betaine and propionylcarnitine, is useful for diagnosis of liver cancer with a supplementary role to α-fetoprotein.
A pathway profile-based method for drug repositioning
The basic hypothesis of this method is that drugs exerting a therapeutic effect may not only directly target the disease-related proteins but also modulate the pathways involved in the pathological process.
Pathway-based drug repositioning using causal inference
The results showed that the proposed computational method for discovering new uses of existing drugs based on casual inference in a layered drug-target-pathway-gene- disease network enables hypothesis generation from public accessible biological data for drug repositioning.
Novel modeling of cancer cell signaling pathways enables systematic drug repositioning for distinct breast cancer metastases.
A computational model is developed to derive specific downstream signaling pathways that reveal previously unknown target-disease connections and new mechanisms for specific cancer subtypes and is applied to reposition drugs based on available patient gene expression data.
Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis
Data suggest that thioridazine may have the potential role in treatment of HCC, and expression of DR5 was higher in tumors than in nontumor adjacent tissues, while DR1 was lower in human hepatocellular carcinoma (HCC).
KEGG for representation and analysis of molecular networks involving diseases and drugs
The new disease/drug information resource named KEGG MEDICUS can be used as a reference knowledge base for computational analysis of molecular networks, especially, by integrating large-scale experimental datasets.
Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway.
The VEGF receptors might play the major role in H CC angiogenesis and prognosis and the differential expression of receptors might prove valuable in selected subsets of patients for tailored antiangiogenic therapy in HCC patients.
Molecular Pathways and Functional Analysis of miRNA Expression Associated with Paclitaxel-Induced Apoptosis in Hepatocellular Carcinoma Cells
The manipulation of one or more of these miRNAs could be an important approach for the improved management of paclitaxel therapy.
The Comparative Toxicogenomics Database's 10th year anniversary: update 2015
The prototype database originally described in its first report has transformed into a sophisticated resource used actively today to help scientists develop and test hypotheses about the etiologies of environmentally influenced diseases.
Phase I clinical trial of liposomal daunorubicin in hepatocellular carcinoma complicating liver cirrhosis.
The toxicity profile observed warns against further assessment of liposomal daunorubicin in patients with hepatocellular carcinoma and liver cirrhosis and there is a need for new active drugs with a safe toxicity profile.